Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Faces Nasdaq Delisting for Low Market Cap

NEW YORK, June 1 (GenomeWeb News) - The Nasdaq exchange told Ciphergen Biosystems last week that it risks being delisted because its market cap has remained below $50 million for 10 consecutive business days.

 

Ciphergen yesterday said it has until June 23 to regain compliance. Its market cap currently stands at $41.4 million, according to Nasdaq.